Keywords: Merck KGaA, Cladribine, Multiple sclerosis, FDA, USA, Delay

US FDA delays Merck KGaA’s cladribine for multiple sclerosis by three months

Article | 26 November 2010

Print This

In a further setback to get an oral multiple sclerosis drug to the market, German drug major Merck KGaA (FWB: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in